1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Netherlands Pharmaceuticals and Healthcare Report Q3 2016

Netherlands Pharmaceuticals and Healthcare Report Q3 2016

  • July 2016
  • -
  • Business Monitor International
  • -
  • 96 pages

Includes 3 FREE quarterly updates

BMI View: The Netherlands has a well establish pharmaceutical and healthcare sector. In 2016, thepharmaceutical market will face yet another year of contraction in value terms before returning to growthin 2017. Medicine sales will be driven by an ageing population and high per capita spending, ensuring thedemand for prescription medicines remains high. However, despite an improvement in economic conditions,the rising cost of healthcare will put considerable pressure on the government to implement further costefficiencies.Headline Expenditure Projections

- Pharmaceuticals: EUR5.82bn (USD6.45bn) in 2015 to EUR5.80bn (USD6.20bn) in 2016; -0.4% inlocal currency terms and -3.9% in US dollar terms. Forecast in line with last quarter.

- Healthcare: EUR72.78bn (USD80.72bn) in 2015 to EUR73.72bn (USD78.89bn) in 2016; +1.3% in localcurrency terms and -2.3% in US dollar terms. Forecast revised downwards from last quarter.

Table Of Contents

Netherlands Pharmaceuticals and Healthcare Report Q3 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Netherlands 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Netherlands 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2012-2020) 17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Netherlands 2012-2020) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Netherlands 2012-2020) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Netherlands 2012-2020) 25
OTC Medicine Market Forecast 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Netherlands 2012-2020) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Netherlands 2014-2020) 30
Table: Pharmaceutical Trade Data And Forecasts local currency (Netherlands 2014-2020) 30
Industry Risk Reward Index 31
Western Europe Risk/Reward Index 31
Netherlands Risk/Reward Index 36
Rewards 36
Risks 36
Regulatory Review 38
Intellectual Property Issues 41
Pricing Regime 41
Reimbursement Regime 43
Market Overview 45
Healthcare Sector 46
Table: Healthcare Resources (Netherlands 2010-2015) 48
Table: Healthcare Personnel (Netherlands 2010-2015) 48
Table: Healthcare Activity (Netherlands 2010-2015) 49
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006 51
Table: Biosimilars Approved In The EU 54
Research and Development 55
Clinical Trials 56
Epidemiology 57
Competitive Landscape 60
Research-Based Industry 60
Table: Pharmaceutical Production, 1995-2010 (EUR '000s) 60
Generic Drugmakers 61
Table: Multinational Market Activity 62
Pharmaceutical Distribution 62
Pharmaceutical Retail Sector 63
Company Profile 66
DSM 66
GlaxoSmithKline 69
Merck and Co 71
Novartis 73
Pfizer 75
Pharming Group 77
Qiagen 80
Sanofi 83
Demographic Forecast 85
Demographic Outlook 85
Table: Population Headline Indicators (Netherlands 1990-2025) 86
Table: Key Population Ratios (Netherlands 1990-2025) 86
Table: Urban/Rural Population and Life Expectancy (Netherlands 1990-2025) 87
Table: Population By Age Group (Netherlands 1990-2025) 87
Table: Population By Age Group % (Netherlands 1990-2025) 88
Glossary 90
Methodology 92
Pharmaceutical Expenditure Forecast Model 92
Healthcare Expenditure Forecast Model 92
Notes On Methodology 93
Risk/Reward Index Methodology 94
Index Overview 95
Table: Pharmaceutical Risk/Reward Index Indicators 95
Indicator Weightings 96

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7 500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7 000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6 860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.